These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2416231)

  • 21. Hydroxyurea increases fetal hemoglobin production in sickle cell anemia.
    Platt OS; Orkin SH; Dover G; Beardsley GP; Miller B; Nathan DG
    Trans Assoc Am Physicians; 1984; 97():268-74. PubMed ID: 6085528
    [No Abstract]   [Full Text] [Related]  

  • 22. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin.
    Humphries RK; Dover G; Young NS; Moore JG; Charache S; Ley T; Nienhuis AW
    J Clin Invest; 1985 Feb; 75(2):547-57. PubMed ID: 2579100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of variable doses of 5-azacytidine on fetal hemoglobin production in sickle cell anemia.
    Dover GJ; Charache SH
    Prog Clin Biol Res; 1984; 165():73-83. PubMed ID: 6209731
    [No Abstract]   [Full Text] [Related]  

  • 24. Increasing fetal hemoglobin production in sickle cell disease: results of clinical trials.
    Dover GJ; Charache S
    Prog Clin Biol Res; 1987; 251():455-66. PubMed ID: 2448813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The biophysics of sickle cell hydroxyurea therapy.
    Eaton WA; Hofrichter J
    Science; 1995 May; 268(5214):1142-3. PubMed ID: 7539154
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies.
    Stamatoyannopoulos JA; Nienhuis AW
    Annu Rev Med; 1992; 43():497-521. PubMed ID: 1374600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene switching -- a new therapeutic epoch: discussion paper.
    Nalbandian RM; Cypress GC
    J R Soc Med; 1984 Mar; 77(3):217-20. PubMed ID: 6199499
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacologic induction of fetal hemoglobin synthesis: cellular and molecular mechanisms.
    Yang YM; Pace B
    Pediatr Pathol Mol Med; 2001; 20(1):87-106. PubMed ID: 12673846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapies to increase fetal hemoglobin in sickle cell disease.
    Steinberg MH
    Curr Hematol Rep; 2003 Mar; 2(2):95-101. PubMed ID: 12901139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia.
    Fibach E; Prasanna P; Rodgers GP; Samid D
    Blood; 1993 Oct; 82(7):2203-9. PubMed ID: 7691251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of hydroxyurea on fetal hemoglobin production in vitro.
    Miller BA; Platt O; Hope S; Dover G; Nathan DG
    Blood; 1987 Dec; 70(6):1824-9. PubMed ID: 2445401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
    Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
    Platt OS; Orkin SH; Dover G; Beardsley GP; Miller B; Nathan DG
    J Clin Invest; 1984 Aug; 74(2):652-6. PubMed ID: 6205021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe beta-thalassemia.
    Nienhuis AW; Ley TJ; Humphries RK; Young NS; Dover G
    Ann N Y Acad Sci; 1985; 445():198-211. PubMed ID: 2409872
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
    Goldberg MA; Brugnara C; Dover GJ; Schapira L; Charache S; Bunn HF
    N Engl J Med; 1990 Aug; 323(6):366-72. PubMed ID: 1695325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of burst-forming-unit-erythroid progenitors and their DNA-synthesis stage to fetal hemoglobin levels in hydroxyurea-treated patients with sickle cell anemia.
    Mankad VN; Baliga S; Phillips K; Shah AK; Yang YM
    Am J Hematol; 1994 Aug; 46(4):259-63. PubMed ID: 7518649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of fetal hemoglobin in the treatment of sickle cell disease.
    Fathallah H; Atweh GF
    Hematology Am Soc Hematol Educ Program; 2006; ():58-62. PubMed ID: 17124041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic manipulation of fetal hemoglobin synthesis.
    Dover GJ; Humphries RK; Young N; Ley T; Boyer S; Charache S; Nienhuis A
    Prog Clin Biol Res; 1985; 191():447-54. PubMed ID: 2413480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimulation of fetal hemoglobin production by hydroxyurea in sickle cell anemia.
    Dover GJ; Charache S
    Prog Clin Biol Res; 1989; 316B():295-306. PubMed ID: 2482499
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
    Musallam KM; Taher AT; Cappellini MD; Sankaran VG
    Blood; 2013 Mar; 121(12):2199-212; quiz 2372. PubMed ID: 23315167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.